RxDoctor Payments Data

Michelle Li

Medical · Dumont, NJNPI 1932506094

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 30.8% of the total. Reporting peaked in 2023 at $2,036 and has fallen 60.1% since, to $812 in 2025. Among medical clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,665in general payments, 2019–2025

Across 217 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$1K
  • GSK$544
  • IBSA Pharma Inc.$432
  • Amgen$385
  • Sanofi$293
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,658100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,665 in reported general payments places this provider in the 90th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl322$149,255
JardianceEmpagliflozin50$43,071
JanuviaSitagliptin Phosphate41$32,081
VemlidyTenofovir Alafenamide21$31,815
RybelsusSemaglutide26$29,841
OzempicSemaglutide20$26,928
JanumetSitagliptin Phos/Metformin Hcl21$17,491
RestasisCyclosporine22$16,390
EliquisApixaban16$16,186
LinzessLinaclotide20$14,787
SynjardyEmpagliflozin/Metformin Hcl21$14,732
JentaduetoLinagliptin/Metformin Hcl19$13,929
Diclofenac Epolamine41$12,828
Jentadueto XrLinagliptin/Metformin Hcl16$7,995
Icosapent Ethyl38$7,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Jentadueto, Jentadueto Xr$259$79,727106 claims
Novo NordiskRybelsus, Ozempic$259$56,76946 claims
MerckJanuvia, Janumet$104$49,57262 claims
AbbVieRestasis, Linzess, Synthroid$2,052$31,93454 claims
GileadVemlidy$1,315$31,81521 claims
GSKShingrix$544$2,63615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 medical providers in New Jersey.

Other medical in Dumont

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →